PMID- 16926602
OWN - NLM
STAT- MEDLINE
DCOM- 20060921
LR  - 20060823
IS  - 0041-1337 (Print)
IS  - 0041-1337 (Linking)
VI  - 82
IP  - 4
DP  - 2006 Aug 27
TI  - Immunoglobulin therapy for plasma cell-rich rejection in the renal allograft.
PG  - 567-9
AB  - Plasma cell-rich acute rejection (PCAR) is associated with poor allograft outcome 
      in renal transplantation. Previous studies report a graft half-life of six months 
      after a single PCAR episode. However, the management of this condition is 
      unclear. Intravenous immunoglobulin (IVIG) therapy, by virtue of its 
      immunomodulating properties, and its influence on B-cell maturation into plasma 
      cells, may be a good candidate for reversing this type of rejection. We report 
      four episodes of PCAR in two patients who responded well to IVIG with improvement 
      in renal function.
FAU - Adrogue, Horacio E
AU  - Adrogue HE
AD  - Nephrology Section, Baylor College of Medicine, The Methodist Hospital, Houston, 
      TX, USA. horacioa@bcm.edu
FAU - Soltero, Liliana
AU  - Soltero L
FAU - Land, Geoffrey A
AU  - Land GA
FAU - Ramanathan, Venkataraman
AU  - Ramanathan V
FAU - Truong, Luan D
AU  - Truong LD
FAU - Suki, Wadi N
AU  - Suki WN
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Adult
MH  - Female
MH  - Graft Rejection/*drug therapy/pathology
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Kidney Transplantation/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Plasma Cells/*pathology
MH  - Transplantation, Homologous
EDAT- 2006/08/24 09:00
MHDA- 2006/09/22 09:00
CRDT- 2006/08/24 09:00
PHST- 2006/08/24 09:00 [pubmed]
PHST- 2006/09/22 09:00 [medline]
PHST- 2006/08/24 09:00 [entrez]
AID - 00007890-200608270-00018 [pii]
AID - 10.1097/01.tp.0000231922.11453.ec [doi]
PST - ppublish
SO  - Transplantation. 2006 Aug 27;82(4):567-9. doi: 10.1097/01.tp.0000231922.11453.ec.